Medical Treatment in Coronary Patients: Is there Still a Gender Gap? Results from European Society of Cardiology EUROASPIRE V Registry

Vynckier P., Ferrannini G., Ryden L., Tokgozoglu L., Bruthans J., Kotseva K., ...More

CARDIOVASCULAR DRUGS AND THERAPY, vol.35, no.4, pp.801-808, 2021 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 35 Issue: 4
  • Publication Date: 2021
  • Doi Number: 10.1007/s10557-020-07095-6
  • Journal Name: CARDIOVASCULAR DRUGS AND THERAPY
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, PASCAL, Agricultural & Environmental Science Database, BIOSIS, CAB Abstracts, EMBASE, International Pharmaceutical Abstracts, MEDLINE, Veterinary Science Database
  • Page Numbers: pp.801-808
  • Keywords: EUROASPIRE, Medical treatment, Cardiovascular diseases, Gender, CARDIOVASCULAR RISK-FACTORS, HEART-DISEASE, MYOCARDIAL-INFARCTION, SEX-DIFFERENCES, PREVENTION, MANAGEMENT, SYMPTOMS, OUTCOMES, WOMEN, AGE
  • Hacettepe University Affiliated: Yes

Abstract

Purpose This study is aimed at investigating gender differences in the medical management of patients with coronary heart disease (CHD). Methods Analyses were based on the ESC EORP EUROASPIRE V (European Survey Of Cardiovascular Disease Prevention And Diabetes) survey. Consecutive patients between 18 and 80 years, hospitalized for a coronary event, were included in the study. Information on cardiovascular medication intake at hospital discharge and at follow-up (>= 6 months to < 2 years after hospitalization) was collected. Results Data was available for 8261 patients (25.8% women). Overall, no gender differences were observed in the prescription and use of cardioprotective medication like aspirin, beta-blockers, and ACE-I/ARBs (P > 0.01) at discharge and follow-up respectively. However, a statistically significant difference was found in the use of statins at follow-up, in disfavor of women (82.8% vs. 77.7%;P < 0.001). In contrast, at follow-up, women were more likely to use diuretics (31.5% vs. 39.5%;P < 0.001) and calcium channel blockers (21.2% vs. 28.8%;P < 0.001), whereas men were more likely to use anticoagulants (8.8% vs. 7.0%;P < 0.001). Overall, no gender differences were found in total daily dose intake (P > 0.01). Furthermore, women were less likely than men to have received a CABG (20.4% vs. 13.2%;P < 0.001) or PCI (82.1% vs. 74.9%; P < 0.001) at follow-up. No gender differences were observed in prescribed (P = 0.10) and attended (P = 0.63) cardiac rehabilitation programs. Conclusion The EUROASPIRE V results show only limited gender differences in the medical management of CHD patients. Current findings suggest growing awareness about risk in female CHD patients.